This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis
Study objective
To assess the cost-effectiveness of a universal childhood hepatitis A vaccination programme in Brazil.
Interventions
Two strategies were compared: universal childhood hepatitis A vaccination programme in the second year of life and the current strategy (vaccination of high risk persons). Universal vaccination comprised two vaccine doses administered six months apart in the second year of life. High risk individuals included patients at risk of serious illness such as those with chronic liver disease, coagulopathy, haemoglobinopathy, cystic fibrosis, persons aged 13 years or less with HIV infection, carriers of hepatitis B and C virus, immunocompromised hosts and candidates for donor and transplant organs.
Location/setting
Brazil/outpatient/in-patient
Methods

Analytical approach:
An age-and time-dependent dynamic model was developed to estimate incidence of hepatitis A over a 30-year period. The model accounted for the herd effects of a universal immunisation programme. The analysis was run separately for low endemicity areas (North, Northeast and Midwest macro-regions, referred to as the North model) and high endemicity areas (South and Southeast regions, referred to as the South model). A decision model was used to estimate health services utilisation and costs of the two strategies. The authors stated that the analysis was conducted from health system and societal perspectives.
Effectiveness data:
Various sources were used to derive estimates for prevalence of hepatitis A, age-specific proportions of icteric cases, vaccine coverage, wastage rates and herd effects. These included primary data collection, Nation Health Information Systems, literature and authors' assumptions. Endemicity estimates for hepatitis A were based on data from a nationwide population survey of seroprevalence of hepatitis conducted across the 27 Brazilian state capitals. The authors stated that the base case assumed effective coverage of 85% (94% vaccine efficacy and 90% vaccination coverage) and wastage rate of 5%. Waning immunity was not considered. The model incorporated a variable force of infection accounting for herd effects of a universal immunisation programme. The current vaccine strategy was assumed to have no effects on transmission of hepatitis A due to its low coverage.
Monetary benefit and utility valuations:
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
Copyright © 2020 University of York
Not applicable.
Measure of benefit:
The benefit was measured in terms of cases averted, deaths averted and life-years saved. Future benefits were discounted at 5%.
Cost data:
Two perspectives were presented. The analysis conducted from the health system perspective included direct medical costs such as medical visits, diagnostics tests, medications and hospitalisations (including liver transplantation and follow-up post-transplantation). The analysis conducted from the societal perspective incorporated family transportation costs and indirect costs (lost productivity) and all direct medical costs. Lost productivity was considered for the patient or caregivers (assumed to be the mother) for children aged under 15 years. Lost productivity was calculated by multiplying the estimated number of working days lost by the national average wage for women. Costs were derived from various sources such as the Brazilian Medical Association, Brazilian National Immunization Program (2008), Hospitalization Information System registers, a national household survey, National Agency of Transplantation, State of Sao Paulo System for Transplantation, Notifiable Diseases Information System, authors' assumptions and expert opinion. Costs were reported in 2008 Brazilian Real (R$). Future costs were discounted at 5%.
Analysis of uncertainty:
Due to uncertainty around baseline parameter values, univariate and bivariate sensitivity analysis on key parameters, such as the frequency of icteric cases, rates of hospitalisation, liver transplantation, vaccine price and outpatient care costs. A reduction of 1% a year in the incidence of hepatitis A due to improvement in sanitary conditions was considered in the sensitivity analyses.
Results
World Health Organisation (WHO) criteria for DALYs (disability-adjusted life-years) averted related to country GDP (gross domestic product) was used as a threshold for cost-effectiveness. Results were presented in full in the paper; only life-years gained outcomes and societal costs are presented here.
For the North model (low endemicity), compared to standard care, universal vaccination resulted in 14,263 life-years gained (67% reduction in life-years lost). From a societal perspective standard care disease treatment cost was R$7,994,666,912 and universal vaccination disease treatment cost was R$4,146,691,719 (48% reduction). The intervention cost (cost of vaccine plus administration, accounting for wastage and coverage) for the current strategy was R$13,449,071 and the universal vaccination intervention cost was R$1, 563,205,826. For the South model (high endemicity) universal vaccination resulted in 26,153 life-years gained (62% reduction in life years lost). The current vaccination strategy disease treatment cost was R$13,863,427,939 and universal vaccination disease treatment cost was R$7,082,620,447 (49% reduction). The intervention cost was R$62,496,666 for current practice and R$1,512,334,409 for universal vaccination.
Universal vaccination was the dominant strategy (more effective and less expensive than the current vaccination strategy) for the base case analysis under both perspectives and for all regions of Brazil.
The intervention remained dominant for all of the bivariate sensitivity analyses and for most of the univariate sensitivity analyses. The results were most sensitive to changes in the percentage of symptomatic infection, vaccine price and outpatient costs.The results in the South model were more robust than the North and national models.
